SRR1101421
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.523
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.387
- PANCREAS_BETA_CELLS+0.385
- FATTY_ACID_METABOLISM+0.265
- HEDGEHOG_SIGNALING+0.224
- KRAS_SIGNALING_DN+0.199
- XENOBIOTIC_METABOLISM+0.164
- ADIPOGENESIS+0.162
- PEROXISOME+0.116
- SPERMATOGENESIS+0.113
Top 10 suppressed
- G2M_CHECKPOINT-0.496
- E2F_TARGETS-0.465
- TGF_BETA_SIGNALING-0.402
- WNT_BETA_CATENIN_SIGNALING-0.371
- TNFA_SIGNALING_VIA_NFKB-0.339
- INTERFERON_GAMMA_RESPONSE-0.332
- INTERFERON_ALPHA_RESPONSE-0.312
- IL6_JAK_STAT3_SIGNALING-0.307
- INFLAMMATORY_RESPONSE-0.304
- ALLOGRAFT_REJECTION-0.296
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3FFD7969-3D39-4219-B3C5-A9FF0C127724 | — | — | 0.920 |
| 2 | SRR1402900 | GTEX | — | 0.914 |
| 3 | SRR1420984 | GTEX | — | 0.906 |
| 4 | SRR1435020 | GTEX | — | 0.905 |
| 5 | SRR1468514 | GTEX | — | 0.902 |
| 6 | SRR1421177 | GTEX | — | 0.901 |
| 7 | SRR807591 | GTEX | — | 0.895 |
| 8 | SRR1318426 | GTEX | — | 0.891 |
| 9 | SRR1415095 | GTEX | — | 0.890 |
| 10 | SRR1326179 | GTEX | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.523 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.387 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.385 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.265 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.224 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.199 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.164 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.162 | Inavolisib | — uncovered |
| PEROXISOME | 0.116 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.113 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.104 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.096 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.096 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.091 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.087 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.047 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.046 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.035 | Inavolisib | — uncovered |